Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors

PURPOSE: This multicenter phase 2 study assessed the tolerability and efficacy of motesanib, an oral inhibitor of Kit, platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptors (VEGFR), in patients with imatinib-resistant gastrointestinal stromal tumors (GIST)...

Descripción completa

Detalles Bibliográficos
Autores principales: Benjamin, Robert S., Schöffski, Patrick, Hartmann, Jörg Thomas, Van Oosterom, Allan, Bui, Binh Nguyen, Duyster, Justus, Schuetze, Scott, Blay, Jean-Yves, Reichardt, Peter, Rosen, Lee S., Skubitz, Keith, McCoy, Sheryl, Sun, Yu-Nien, Stepan, Daniel E., Baker, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123696/
https://www.ncbi.nlm.nih.gov/pubmed/20838998
http://dx.doi.org/10.1007/s00280-010-1431-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123696/
https://www.ncbi.nlm.nih.gov/pubmed/20838998
http://dx.doi.org/10.1007/s00280-010-1431-9

Ejemplares similares